PHAT Phathom Pharmaceuticals

Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020

Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020

FLORHAM PARK, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that Terrie Curran, President and Chief Executive Officer, and Azmi Nabulsi, M.D., Chief Operating Officer, will present at Cowen and Company’s 40th Annual Healthcare Conference in Boston on March 2, 12:00 pm EST at the Boston Marriott Copley Place.

To access the live webcast and archived recordings for this presentation, visit the Investors & Media section of the Phathom Pharmaceuticals website at .

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company’s website at .

Follow Phathom on LinkedIn at .

CONTACTS

Media Contacts:

Joe Hand

1-877-742-8466

Nick Benedetto

1-877-742-8466

Investor Contact:

Patti Bank

Westwicke Partners

415-513-1284

EN
25/02/2020

Underlying

PHATPhathom Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Phathom Pharmaceuticals

 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Fina...

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of $55.9 million; non-GAAP operating expenses of $50.3 million and net cash usage of approximately $5.2 million, reflecting continued expense discipline Strengthened financial position through $130 million equity offering and modification of term debt Providing FY 2026 guidanc...

20h / 53m 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals to Participate in Upcoming Investor Conference...

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference in Boston, MADate: Monday, March 2, 2026Company Presentation: 10:30 am ESTManagement to participate in one-on-one mee...

February 23, 2026 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Fi...

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026 Management to host conference call on Thursday, February 26, 2026, at 8:00 am EST FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 fina...

February 17, 2026 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook ...

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team will participate in a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026 on Thursday, February 12, 2026, at 11:30 am EST. Company management will also participate in one-on-one meetings during the conference, wh...

February 5, 2026 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offer...

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today the pricing of an underwritten public offering of 6,875,000 shares of its common stock and pre-funded warrants to purchase 1,250,078 shares of common stock. The shares of common stock are being sold to the public at a price of $16.00 per shar...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch